Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Target Price at $68.20

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $68.20.

Several equities analysts have weighed in on LMAT shares. Barrington Research raised their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Finally, StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, March 23rd.

Insiders Place Their Bets

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now owns 5,309 shares in the company, valued at $358,357.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares in the company, valued at $148,817,393.78. The disclosure for this sale can be found here. In the last three months, insiders sold 114,036 shares of company stock valued at $7,873,749. Company insiders own 12.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. BlackRock Inc. lifted its position in shares of LeMaitre Vascular by 0.8% during the third quarter. BlackRock Inc. now owns 3,267,883 shares of the medical instruments supplier’s stock worth $165,616,000 after purchasing an additional 26,787 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in LeMaitre Vascular by 0.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock worth $109,432,000 after buying an additional 10,390 shares during the period. Vanguard Group Inc. lifted its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares in the last quarter. Copeland Capital Management LLC boosted its position in LeMaitre Vascular by 2.3% in the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock valued at $71,515,000 after buying an additional 28,720 shares during the last quarter. Finally, Ranger Investment Management L.P. grew its stake in shares of LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after acquiring an additional 13,681 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $66.36 on Friday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 49.52, a price-to-earnings-growth ratio of 2.90 and a beta of 0.88. The business’s 50 day simple moving average is $63.34 and its 200-day simple moving average is $56.95. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The company had revenue of $48.90 million for the quarter, compared to the consensus estimate of $49.01 million. During the same period in the previous year, the business earned $0.25 earnings per share. LeMaitre Vascular’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were paid a dividend of $0.16 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.14. The ex-dividend date was Wednesday, March 13th. This represents a $0.64 annualized dividend and a dividend yield of 0.96%. LeMaitre Vascular’s dividend payout ratio is presently 47.76%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.